Highlights Neurogene Inc.

Equities

NGNE

US64135M1053

Real-time Estimate Cboe BZX Other stock markets 07:28:22 14/05/2024 pm IST			5-day change	1st Jan Change
30.9 ^USD	+0.86%		-8.63%	+60.01%

10/05	Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
07/05	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting	07/05	CI
North American Morning Briefing : Stocks Struggle After New Records	22/03	DJ
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03	CI
North American Morning Briefing : Inflation -2-	15/03	DJ
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	04/03	CI
Neurogene Announces Business Update and 2024 Outlook	05/01	CI
Neurogene Completes Merger With Neoleukin Therapeutics	19/12	MT
Neurogene Inc. completed the acquisition of Neoleukin Therapeutics, Inc. from a group of shareholders for approximately $120 million in a reverse merger transaction.	18/12	CI
Neoleukin Therapeutics Board Approves Reverse Stock Split, Increase in Authorized Common Stock Capital to 500 Million	15/12	MT
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Neoleukin Therapeutics Board Approves 1-for-5 Reverse Stock Split	22/23/22	MT
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Neoleukin Therapeutics to Merge With Neurogene in All-Stock Deal	18/23/18	MT
Neurogene Inc. entered into a definitive merger agreement to acquire Neoleukin Therapeutics, Inc. in a reverse merger transaction.	18/23/18	CI
Neoleukin Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09	CI
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	10/22/10	CI
Neoleukin Therapeutics, Inc. Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating Nl-201 in Combination with Keytruda® (Pembrolizumab)	16/22/16	CI
Neoleukin Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	10/22/10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Neurogene Inc.

Equities

NGNE

US64135M1053

Highlights

Filters